>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Calcium Channel>>Carboxyamidotriazole Orotate

Carboxyamidotriazole Orotate (Synonyms: L-651582 Orotate; CAI Orotate)

Catalog No.GC39646

카르복시아미도트리아졸 오로테이트(L-651582 오로테이트)는 경구 생체이용 가능한 신호 전달 억제제인 카르복시아미도트리아졸(CAI)의 오로테이트 염 형태입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Carboxyamidotriazole Orotate Chemical Structure

Cas No.: 187739-60-2

Size 가격 재고 수량
5mg
US$180.00
재고 있음
10mg
US$270.00
재고 있음
50mg
US$765.00
재고 있음
100mg
US$1,080.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects[1][2].

[1]. Corrado C, et al. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. PLoS One. 2012;7(8):e42310. [2]. Hussain MM, et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol. 2003 Dec 1;21(23):4356-63.

리뷰

Review for Carboxyamidotriazole Orotate

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Carboxyamidotriazole Orotate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.